Clinical Trial Update: Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety and efficacy of CC-4047 in patients with metastatic hormone-refractory prostate cancer has completed, reporting results from t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CC-4047

Snippet

Sponsor: Celgene Corporation | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED